PF-05280602 Uses, Dosage, Side Effects and more
PF-05280602 is under investigation in clinical trial NCT01439971 (Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia).
| Trade Name | PF-05280602 |
| Generic | Marzeptacog alfa (activated) |
| Marzeptacog alfa (activated) Other Names | Marzeptacog alfa (activated), PF-05280602 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
